Net Cash Provided by (Used in) Financing Activities of Keenova Therapeutics plc from 29 Dec 2017 to 28 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Keenova Therapeutics plc quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 29 Dec 2017 to 28 Mar 2025.
  • Keenova Therapeutics plc Net Cash Provided by (Used in) Financing Activities for the quarter ending 28 Mar 2025 was $3,100,000, a 41% decline year-over-year.
  • Keenova Therapeutics plc annual Net Cash Provided by (Used in) Financing Activities for 2024 was $846,400,000.
  • Keenova Therapeutics plc annual Net Cash Provided by (Used in) Financing Activities for 2021 was $137,500,000, a 26% increase from 2020.
  • Keenova Therapeutics plc annual Net Cash Provided by (Used in) Financing Activities for 2020 was $185,600,000, a 34% increase from 2019.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Keenova Therapeutics plc Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $3,100,000 -$900,000 -41% 28 Dec 2024 28 Mar 2025 10-Q 12 May 2025 2025 Q1
Q1 2024 $2,200,000 +$8,800,000 +80% 30 Dec 2023 29 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $102,200,000 15 Nov 2023 29 Dec 2023 10-K 13 Mar 2025 2024 FY
Q1 2023 $11,000,000 -$6,400,000 -139% 31 Dec 2022 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q3 2022 $17,300,000 17 Jun 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $1,700,000 17 Jun 2022 01 Jul 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $4,600,000 +$114,300,000 +96% 01 Jan 2022 01 Apr 2022 10-Q 09 May 2023 2023 Q1
Q1 2021 $118,900,000 -$110,000,000 -1236% 26 Dec 2020 26 Mar 2021 10-Q 03 May 2022 2022 Q1
Q1 2020 $8,900,000 +$239,500,000 +96% 28 Dec 2019 27 Mar 2020 10-Q 04 May 2021 2021 Q1
Q1 2019 $248,400,000 29 Dec 2018 29 Mar 2019 10-Q 06 May 2020 2020 Q1

Keenova Therapeutics plc Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $846,400,000 30 Dec 2023 27 Dec 2024 10-K 13 Mar 2025 2024 FY
2021 $137,500,000 +$48,100,000 +26% 26 Dec 2020 31 Dec 2021 10-K 26 Mar 2024 2023 FY
2020 $185,600,000 +$94,500,000 +34% 28 Dec 2019 25 Dec 2020 10-K 03 Mar 2023 2022 FY
2019 $280,100,000 +$814,900,000 +74% 29 Dec 2018 27 Dec 2019 10-K 15 Mar 2022 2021 FY
2018 $1,095,000,000 -$964,800,000 -741% 30 Dec 2017 28 Dec 2018 10-K 10 Mar 2021 2020 FY
2017 $130,200,000 31 Dec 2016 29 Dec 2017 10-K 26 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.